Extension Study of IMO-8400 in Patients With Waldenström's Macroglobulinemia Who Completed Study 8400-401

NCT02363439 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

5

Enrollment

INDUSTRY

Sponsor class

Conditions

Waldenstrom's Macroglobulinemia

Interventions

DRUG: IMO-8400 0.6 mg/kg/wk or 1.2 mg/kg twice weekly

Sponsor

Idera Pharmaceuticals, Inc.